Health Catalyst (NASDAQ: HCAT) exec to sell 28,875 restricted shares via MS
Filing Impact
Filing Sentiment
Form Type
144
Rhea-AI Filing Summary
Health Catalyst, Inc. filing notifies a proposed sale of 28,875 restricted common shares to be sold on 02/26/2026. The sale is listed as compensation stock and identifies Morgan Stanley Smith Barney LLC at 1 New York Plaza as the broker.
The filing names Daniel Burton and shows prior restricted stock sales of 55,715 shares on 12/01/2025 for $161,584.64. Shares outstanding are listed as 70,730,884 as of 02/26/2026.
Positive
- None.
Negative
- None.
FAQ
What does the HCAT Form 144 disclose about planned sales?
The Form 144 discloses a proposed sale of 28,875 restricted common shares on 02/26/2026. The filing lists the sale as compensation stock and names Morgan Stanley Smith Barney LLC as broker.
Who is the reporting person on the HCAT Form 144?
The filing names Daniel Burton in connection with the restricted stock transactions. The document links prior sales by the same person and the planned sale scheduled for 02/26/2026.
What prior transactions are shown in the HCAT excerpt?
The excerpt shows prior restricted stock sales of 55,715 shares on 12/01/2025 with an aggregate value of $161,584.64. These sales are reported in the ‘‘past 3 months’’ section of the form.
Which broker is handling the proposed HCAT sale?
The proposed 28,875 share sale lists Morgan Stanley Smith Barney LLC at 1 New York Plaza, New York, NY, as the broker for transactions scheduled on 02/26/2026.